Grand Marina - Helsinki Finland
Wednesday September 7, 2011
Breakfast & Registration
Investing in Neurotech - Panel Discussion
A diverse panel of private, public and strategic investors will discuss their investment strategies. What are investors looking for to balance the risks and opportunities in neurotech? What are the benefits of business models in devices, pharmaceuticals, diagnostics and information technology in the EU? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Killu Sanborn, Director of Business Development, Oxford Finance
Johan Christenson, Partner, HealthCap
Kent Hansen, Deutsche Bank Private Equity
Thom Rasche, Partner, Early Bird Venture Capital
Carole Nuechterlein, Head, Roche Venture Fund
Networking and Refreshment Break
Alzheimer's and Cognitive Disorders
As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
Session Chair: Alexandra Goll, General Partner, TVM Capital
Konrad Glund, CEO, Probiodrug
Hampus Hillerstrom, Executive VP & CBO, NeuroPhage
Loic Maurel, CEO, ExonHit
Strategies for CNS Drug and Device Development
Intelligent preclinical screening and clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving drug and device development to navigate a path to approval. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.
Session Chair: John Reppas, Director of Public Policy, Neurotech Industry Organization
Rick Stewart, Chairman and CEO, Ricanto
Beth Fordham-Meier, VP, Licensing and IP, Targacept
Vanessa Edwards, Partner, EU Regulatory Practice, K&L Gates
Movement Disorders: Parkinson's, Huntington's, and ALS
Exciting developments are in the pipeline for slowing progression of some of the most vexing neurological conditions like ALS, Huntinton's and Parkinson's. What is the latest science behind new targets for these disorders. Can active doctor and patient populations and high prices offset small markets in orphan indications?
Session Chair: Alethia de Leon, Head of Search and Evaluation, Neuroscience & Opthal., Global Business Development & Licensing, Novartis
Patrik Dahlen, CEO, NeuroSearch
Juhani Ladenpera, CEO, Hermo Pharma
Ulf Ljungberg, President and CEO, NeuroNova
Sjaak Deckers, CEO, Sapiens Steering Brain Stimulation
Internal and External Research & Development
What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? How can outlicensing and spin out opportunities be leveraged? What opportunities exist for discovery partnerships and early development collaborations?
Session Chair: Hakan Goker, Principal, Aescap Venture
Jeffrey Erb, Business Development, Alliances, and IP Management, Medtronic
Mark Farmery, Neuroscience Business Development, AstraZeneca
Theo Meert, Head of Neuroscience, Johnson & Johnson
Shafique Virani, Global Head, CNS Bus. Dev. and Licensing, Hoffmann La-Roche
Networking and Refreshment Break
Acute and Traumatic Injury: Stroke and TBI
New hope is emerging for treatments of major traumatic injuries to the central nervous system. While highly challenging, companies are leveraging innovative financing to address these unmet markets.
Session Chair: Andreas Jeromin, Business Development, Banyan Biomarkers
Mikael Bronnegard, CEO, NeuroVive Pharmaceuticals
Brian Leuthner, CEO, Edge Therapeutics
Don Picker, CEO, Sinapis Pharma
Daniel Green, CEO, Phagenesis Ltd.
Thursday September 8, 2011
Breakfast & Registration
Partnering, Licensing and Acquisitions in Neurotech
Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in licensing and acquisitions? What are priority indications and stage of development requirements? What are the opportunities for neurodevice companies and who is interested in acquiring novel technology?
Session Chair: Francesco de Rubertis, Partner, Index Ventures
Richard Brudnick, Senior Director Business Development, Biogen Idec
Lubor Gaal, Head of Europe, Strategic Transactions Group, Bristol-Myers Squibb
Hans Christian Keller, Associate Director, Business Development, Lundbeck
Erik Lund, Director Worldwide Licensing, Merck
Novel Drug, Device and Diagnostic Platforms
Next Generation Psychiatry
Schizophrenia, anxiety, depression, ADHD, and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?
Session Chair: Bruce Leuchter, Managing Director, OPN Capital Markets
Erik Buntinx, CEO, PharmaNeuroBoost
Eric Meier, CEO, NeoStim
Timo Veromaa, CEO, Biotie Therapies
Dinah Weissmann, CEO, BioCortech
Cutting Edge Translational Research and The Future of Treatment Development
This session will feature selected cutting-edge research projects and licensing opportunities from academia and research institutes. How do these novel projects shift the future of CNS treatment development? Where should research be headed to avoid the problems of past generation therapeutics and devices?
Session Chair: Casey Lynch, Managing Director, NeuroInsights
“The role of environment, genes and brain development on CNS drug effects”
Eero Castren, Research Director, Neuroscience Center, University of Helsinki
"New animal models of neurodegeneration, depression and anxiety"
Wolfgang Wurst, Director of the Institute of Developmental Genetics at the National Research Centre for Environment and Health and Professor at University Munich
"IMANE: Collaborating to develop next generation intelligent neurodevices"
Peter Bergsma, VP Business Development, Neurotech SA
Refreshment Break, One-on-One Meetings